[ad_1]
The reply is offered in a current white paper by Pearson, Schapiro and Pearson (2022). They use IQVIA knowledge by way of 2020 throughout 389 medication treating 1.8 million people. The research finds that whereas 5% of medication with an orphan indication price greater than $500,000 per yr, these medication make up solely 0.08% of all sufferers handled by medication with an orphan indication. The bulk (52%) of sufferers who obtain therapy an orphan drug get the therapy for <$50,000.
![](https://www.healthcare-economist.com/wp-content/uploads/2022/10/orphan_prices.png)
[ad_2]